Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04095273 | Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug | completed | Phase 1 | 56 | BayerINDUSTRY | 5 | Apr 2, 2024 | clinicaltrials |
| NCT06338436 | Varian ProBeam Proton Therapy System China Clinical Trial (Guangzhou) | completed | N/A | 47 | Varian, a Siemens Healthineers CompanyINDUSTRY | 1 | Apr 2, 2024 |
| clinicaltrials |
| NCT01897571 | Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL | completed | Phase 1 / Phase 2 | 400 | Epizyme, Inc.INDUSTRY | 10 | Mar 26, 2024 | clinicaltrials |
| NCT03590054 | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 | 35 | Rahul AggarwalOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT01738139 | Ipilimumab and Imatinib Mesylate in Advanced Cancer | completed | Phase 1 | 68 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT02022982 | PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors | completed | Phase 1 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT03525925 | Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors | completed | Phase 1 | 16 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT04200963 | A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma | completed | Phase 1 | 78 | Ikena OncologyINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT05231746 | A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001) | completed | Phase 1 | 47 | STCube, Inc.INDUSTRY | 2 | Mar 13, 2024 | clinicaltrials |
| NCT05547906 | Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors | completed | Phase 1 | 18 | MetaFinesINDUSTRY | 2 | Mar 13, 2024 | clinicaltrials |
| NCT01286467 | A Study Of PF-04449913 Administered Alone In Select Solid Tumors | completed | Phase 1 | 23 | PfizerINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04069026 | A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer | completed | Phase 1 | 78 | BayerINDUSTRY | 5 | Mar 6, 2024 | clinicaltrials |
| NCT05732350 | Exploratory Drug Interaction Study Between SMIs and DOACs | completed | — | 37 | Maastricht University Medical CenterOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT00020371 | BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05051241 | A Study of GFH018 in Patients With Advanced Solid Tumors | completed | Phase 1 | 50 | Zhejiang Genfleet Therapeutics Co., Ltd.INDUSTRY | 1 | Mar 1, 2024 | clinicaltrials |
| NCT02034981 | Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1(AcSé) | completed | Phase 2 | 246 | UNICANCEROTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT02140736 | Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology(ORHEO) | completed | — | 2,333 | Hospira, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04552418 | Intestinal Microbiome Modification With Resistant Starch in Patients Treated With Dual Immune Checkpoint Inhibitors | completed | Early Phase 1 | 12 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05809557 | EMR Chemotoxicity Risk Calculator To Decrease Chemotherapy Toxicity | completed | N/A | 34 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06198556 | Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects | completed | Phase 1 | 18 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 28, 2024 | clinicaltrials |
| NCT03523390 | Phase I/Ib Multiple Ascending Dose Study in China | completed | Phase 1 | 24 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05078593 | A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma | completed | Phase 1 | 18 | Shanghai Henlius BiotechINDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT03728179 | RACIN in Patients With Advanced TIL-negative Solid Tumors(RACIN) | completed | Phase 1 | 40 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05248074 | To Evaluate the Safety, Pharmacokinetic and the Effect of Food After Administration of ABN401 in Healthy Adult Volunteers | completed | Phase 1 | 25 | Abion IncINDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05498480 | Study of Relatlimab in Combination With Nivolumab in Chinese Participants(RELATIVITY-111) | completed | Phase 1 | 6 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06266923 | A Clinical Study of SPH6516 Tablets in the Treatment of Advanced Solid Tumors. | completed | Early Phase 1 | 16 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05083338 | Psychological, Psychophysical and Epigenetic Determinants of Chronic Pain After Cytoreductive - Hyperthermic Intraoperative Chemotherapy | completed | — | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT04921878 | A Study of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid Tumors | completed | Phase 1 | 29 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT05400265 | Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor | completed | Phase 1 | 9 | Shanghai Henlius BiotechINDUSTRY | 1 | Feb 6, 2024 | clinicaltrials |
| NCT04857138 | A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 80 | Hoffmann-La RocheINDUSTRY | 5 | Feb 5, 2024 | clinicaltrials |
| NCT03255070 | A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01) | completed | Phase 1 | 106 | Ambrx, Inc.INDUSTRY | 2 | Feb 1, 2024 | clinicaltrials |
| NCT04862767 | TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor | completed | Phase 1 | 9 | AutotelicbioINDUSTRY | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06231277 | Phase I Clinical Trial of BH002 in Patients With Advanced Solid Tumors(BH002-Ⅰ-101) | completed | Phase 1 | 12 | Zhuhai Beihai Biotech Co., LtdINDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT05074472 | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors | completed | Phase 1 / Phase 2 | 35 | ZielBio, Inc.INDUSTRY | 1 | Jan 29, 2024 | clinicaltrials |
| NCT04958226 | A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours | completed | Phase 1 | 21 | AstraZenecaINDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | completed | Phase 1 / Phase 2 | 133 | CytomX TherapeuticsINDUSTRY | 4 | Jan 23, 2024 | clinicaltrials |
| NCT02564900 | Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors | completed | Phase 1 | 292 | Daiichi Sankyo Co., Ltd.INDUSTRY | 2 | Jan 22, 2024 | clinicaltrials |
| NCT05002140 | Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients | completed | Phase 1 | 12 | XRad Therapeutics IncINDUSTRY | 1 | Jan 11, 2024 | clinicaltrials |
| NCT01606878 | Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | completed | Phase 1 | 46 | Children's Oncology GroupNETWORK | 2 | Jan 5, 2024 | clinicaltrials |
| NCT04235101 | Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors | completed | Phase 1 | 32 | Byondis B.V.INDUSTRY | 3 | Jan 5, 2024 | clinicaltrials |
| NCT00486356 | Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer | completed | Phase 1 | 46 | University of NebraskaOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT01206465 | Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors | completed | Phase 1 | 29 | University of NebraskaOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT04439006 | Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization | completed | Phase 1 | 10 | Jennifer WoyachOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT05930457 | Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors | completed | Phase 1 | 15 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT01709435 | Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 2 | Dec 22, 2023 | clinicaltrials |
| NCT00782574 | Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients | completed | Phase 1 | 57 | AstraZenecaINDUSTRY | 2 | Dec 21, 2023 | clinicaltrials |
| NCT03219268 | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms | completed | Phase 1 | 277 | MacroGenicsINDUSTRY | 8 | Dec 21, 2023 | clinicaltrials |
| NCT02808650 | Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 30 | Children's Oncology GroupNETWORK | 1 | Dec 20, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 2, 2024source: clinicaltrials